Evolent Health Inc Class A (EVH)

Evolent Health's stock has experienced significant volatility and a notable decline over the past year. Q4 CY2024 earnings missed analyst expectations, leading to a drop in shares. Q2 2025 earnings also missed forecasts, though the stock saw a slight increase. Evolent Health agreed to sell Evolent Care Partners to Privia Health Group, Inc. for up to $113 million in cash. The company announced a proposed offering of $140.0 million of convertible senior notes due 2031, later priced at $145.0 million, to repurchase existing notes and Class A Common Stock. A significant contract with Aetna for Evolent Health's oncology Performance Suite is set to go live in Q1 2026. Analysts have generally maintained a "Buy" or "Overweight" rating for EVH.

Specific information detailing the demand seasonality for Evolent Health, Inc.'s products and services is not explicitly provided. While investment needs can be seasonal in the context of cash flow, the healthcare technology sector is influenced by factors such as digital transformation, AI adoption, and government incentives, but these do not inherently imply strong seasonality in demand for Evolent Health's specific services.

Evolent Health, Inc. (EVH), founded in 2011 and headquartered in Arlington, Virginia, is a healthcare solutions provider focused on enabling health systems and payers to transition to value-based care models. The company operates in two primary segments: Evolent Health Services, which provides an integrated administrative and clinical platform, including Identifi, and Clinical Solutions, which offers specialty care management services across various medical specialties and Machinify Auth.

Evolent Health serves a diverse client base, including national and regional health plans, integrated health systems, and physician groups across the United States.

Direct information regarding specific events that have negatively impacted Evolent Health's brand reputation in the past year is not readily available. Analyst sentiment towards the company is generally positive, with a consensus rating of "Strong Buy" or "Moderate Buy". The company emphasizes patient-centered care, innovation, operational excellence, and client success.

Evolent Health has a mixed ownership structure, with approximately 41.40% of the company's stock owned by Institutional Investors, 2.20% by Insiders, and 56.40% by Public Companies and Individual Investors. Major institutional shareholders include Vanguard Group Inc, Cadian Capital Management, Lp, and BlackRock, Inc.